This review summarizes current research on biomarkers for distinguishing pediatric vasovagal syncope from postural tachycardia syndrome and predicting personalized treatment outcomes.
Can biomarkers improve the differential diagnosis and personalized treatment of pediatric vasovagal syncope and postural tachycardia syndrome?
Biomarkers offer a promising approach to accurately differentiate and personalize treatment for children with vasovagal syncope and postural tachycardia syndrome.
In children, vasovagal syncope and postural tachycardia syndrome constitute the major types of orthostatic intolerance. The clinical characteristics of postural tachycardia syndrome and vasovagal syncope are similar but their treatments differ. Therefore, their differential diagnosis is important to guide the correct treatment. Therapeutic methods vary in patients with the same diagnosis because of different pathomechanisms. Hence, in patients with vasovagal syncope or postural tachycardia syndrome, routine treatments have an unsatisfactory efficacy. However, biomarkers could increase the therapeutic efficacy significantly, allowing for an accurate and detailed assessment of patients and leading to improved therapeutic effects. In the present review, we aimed to summarize the current state of research into biomarkers for distinguishing the diagnosis of pediatric vasovagal syncope from that of postural tachycardia syndrome. We also discuss the biomarkers that predict treatment outcomes during personalized therapy for each subtype.
Cheng et al. (Tue,) conducted a review in Postural tachycardia syndrome and vasovagal syncope. Biomarkers and Hemodynamic Parameters was evaluated. This review summarizes current research on biomarkers for distinguishing pediatric vasovagal syncope from postural tachycardia syndrome and predicting personalized treatment outcomes.